<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00062686</url>
  </required_header>
  <id_info>
    <org_study_id>EGF20008</org_study_id>
    <nct_id>NCT00062686</nct_id>
    <nct_alias>NCT00068627</nct_alias>
  </id_info>
  <brief_title>GW572016 For Treatment Of Refractory Metastatic Breast Cancer</brief_title>
  <official_title>An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent Therapy in Subjects With Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving HERCEPTIN-Containing Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to determine the efficacy of an oral dual kinase inhibitor for the&#xD;
      treatment of metastatic breast cancer tumors that are known to overexpress ErbB2 in a&#xD;
      refractory patient population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">February 2005</completion_date>
  <primary_completion_date type="Actual">February 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical benefit rate time to progression 4 and 6 month progression free survival overall survival</measure>
  </secondary_outcome>
  <enrollment>200</enrollment>
  <condition>Neoplasms, Breast</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW572016</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed Informed Consent.&#xD;
&#xD;
          -  Histologically confirmed Stage IIIb or IV breast cancer.&#xD;
&#xD;
          -  Refractory breast cancer defined as progression in the metastatic setting after prior&#xD;
             therapy with anthracyclines, taxanes and capecitibine.&#xD;
&#xD;
          -  Subjects with documented ErbB2 tumor overexpression must have received at least 6&#xD;
             cycles of trastuzumab.&#xD;
&#xD;
          -  Documented disease progression of the most recent treatment is required.&#xD;
&#xD;
          -  Archived tumor tissue available for testing.&#xD;
&#xD;
          -  Measurable lesions according to Response Evaluation Criteria In Solid Tumors (RECIST).&#xD;
&#xD;
          -  At least 3 weeks since prior cancer therapies except for trastuzumab which must be&#xD;
             discontinued at least 2 weeks prior to the beginning of study drug.&#xD;
&#xD;
          -  Bisphosphonate therapy initiated prior to study entry is allowed, however, initiation&#xD;
             of bisphosphonates following study entry is not allowed.&#xD;
&#xD;
          -  Able to swallow and retain oral medication.&#xD;
&#xD;
          -  Cardiac ejection fraction within the institutional normal range as measured by&#xD;
             echocardiogram or MUGA (Multiple Gated Acquisition) scan.&#xD;
&#xD;
          -  Adequate kidney and liver function.&#xD;
&#xD;
          -  Adequate bone marrow function.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Pregnant or lactating.&#xD;
&#xD;
          -  Copies of nadir scans and/or photographs of the tumor prior to disease progression as&#xD;
             well as scans documenting disease progression are not available for review.&#xD;
&#xD;
          -  Malabsorption syndrome, ulcerative colitis, disease significantly affecting&#xD;
             gastrointestinal function or resection of the stomach or small bowel.&#xD;
&#xD;
          -  History of other malignancy.&#xD;
&#xD;
          -  Serious medical or psychiatric disorder that would interfere with the patient''s&#xD;
             safety or informed consent.&#xD;
&#xD;
          -  Active or uncontrolled infection.&#xD;
&#xD;
          -  Known history of uncontrolled or symptomatic angina, arrhythmias or congestive heart&#xD;
             failure.&#xD;
&#xD;
          -  Known history of or clinical evidence of leptomeningeal carcinomatosis.&#xD;
&#xD;
          -  Active infection.&#xD;
&#xD;
          -  Concurrent cancer therapy or investigational therapy.&#xD;
&#xD;
          -  Use of oral or IV steroids.&#xD;
&#xD;
          -  Unresolved or unstable serious toxicity from prior therapy.&#xD;
&#xD;
          -  Prior treatment with an ErbB1 and/or ERbB2 inhibitor other than trastuzumab.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1455BWU</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Augsburg</city>
        <state>Bayern</state>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bebington, Wirral</city>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>France</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Greece</country>
    <country>Japan</country>
    <country>Spain</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>June 11, 2003</study_first_submitted>
  <study_first_submitted_qc>June 11, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2003</study_first_posted>
  <last_update_submitted>April 14, 2015</last_update_submitted>
  <last_update_submitted_qc>April 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lapatinib</keyword>
  <keyword>Metastatic Breast Cancer</keyword>
  <keyword>HERCEPTIN refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

